Upsher-Smith Unveils Innovations at Annual Neurology Conference
Upsher-Smith Showcases Innovations at Major Neurology Conference
Upsher-Smith Laboratories, LLC, a trusted name in pharma, is excited to share its innovations at the upcoming major annual meeting of the American Academy of Neurology (AAN). The company is set to present its expanding portfolio tailored for rare diseases, particularly focusing on their flagship product, VIGAFYDE™. This is particularly notable, as VIGAFYDE™ stands out as the first and only ready-to-use liquid vigabatrin solution, aimed specifically at addressing the critical needs of infants diagnosed with infantile spasms.
Introduction of VIGAFYDE™ Oral Solution
VIGAFYDE™ (vigabatrin) Oral Solution is a pivotal development as it is intended for infants aged between 1 month to 2 years. Administered as a monotherapy, its design aims to mitigate the potential risks associated with vision loss. This formulation promises to streamline the medication process, making it easier for caregivers while maximizing effectiveness.
Commitment to Rare Diseases
Upsher-Smith's commitment to the rare disease community remains steadfast and is evident in their robust product offerings, including VIGADRONE® (vigabatrin) Tablets and TORPENZ™ (everolimus) Tablets. The journey for healing and treatment for patients relies heavily on continued innovation and support which Upsher-Smith is determined to provide. Jim Maahs, Head of Commercial at Upsher-Smith, noted that their offerings have significantly expanded since the launch of VIGADRONE® in 2018. Their booth at the conference will be buzzing with rich discussions about these crucial innovations and the future of patient treatments.
The Promise of Support™ Program
Further illustrating their dedication, Upsher-Smith's Promise of Support™ Program provides indispensable resources for patients and healthcare providers alike. This program covers various elements crucial for the continuous support of patients prescribed VIGADRONE®, including assistance with copays for eligible patients, ensuring that financial constraints do not pose a barrier to necessary treatment.
Engagement at the Conference
At the AAN Annual Meeting, Upsher-Smith representatives will be readily available to engage with medical professionals, providing insights into their offerings. Visitors can expect to learn about advanced treatment options, including the unique benefits of VIGAFYDE™ alongside ongoing support programs for patients, caregivers, and healthcare professionals. The interactive experiences at their booth promise to be enlightening, encouraging open dialogue regarding the challenges and solutions in the realm of rare diseases.
Safety Information Regarding VIGAFYDE™
While VIGAFYDE™ represents a significant advancement in the management of infantile spasms, it is imperative to discuss the associated risks. A Risk Evaluation and Mitigation Strategy (REMS) governs all vigabatrin products, underscoring the importance of informed decisions regarding treatment options. Continuous vision monitoring is crucial, and all prescribing healthcare providers must be part of the REMS program to ensure patient safety.
Upsher-Smith: An Overview
In alignment with their commitment to continuous growth and innovation, Upsher-Smith is proud to be a member of the Bora Group, enhancing their capabilities and outreach. Known for a stable supply chain and a strong focus on customer service, Upsher-Smith is fundamentally about improving the health outcomes of patients worldwide.
Frequently Asked Questions
What is VIGAFYDE™?
VIGAFYDE™ is a ready-to-use oral solution of vigabatrin indicated for the treatment of infantile spasms in children.
Where can I find Upsher-Smith's products?
Upsher-Smith's products, including VIGAFYDE™, are available through various healthcare providers and pharmacy partners.
What is the Promise of Support™ Program?
The Promise of Support™ Program offers comprehensive resources, including financial assistance for patients prescribed VIGADRONE®.
How can patients ensure they are monitored while using VIGAFYDE™?
Regular vision testing and engagement with a healthcare provider are vital components of care while using VIGAFYDE™.
What other products does Upsher-Smith offer?
In addition to VIGAFYDE™, Upsher-Smith offers VIGADRONE® Tablets and TORPENZ™ Tablets for the treatment of various conditions.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
